Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025
The 2024/25 influenza season in Europe is currently characterised by the co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness estimates from eight European studies conducted in 17 countries indicate an overall influenza A vaccine effectiveness of 32–53% in primary care settings and 33–56% in hospital settings, with some indications of lower effectiveness by subtype and higher effectiveness against influenza B (≥58% across settings). Where feasible, influenza vaccination should be encouraged and other preventive measures strengthened.
Authors
- Amanda Bolt Botnen (ORCID: https://orcid.org/0000-0003-2200-2747)
- Heather Whitaker (ORCID: https://orcid.org/0000-0001-5833-1863)
- Héloïse Lucaccioni (ORCID: https://orcid.org/0000-0003-3080-9794)
- European IVE group
- Mark G. O’Doherty (ORCID: https://orcid.org/0000-0001-9976-258X)
- Francisco Pozo
- Ramona Trebbien
- Mark Hamilton
- Nick Andrews
- Karina Lauenborg Møller
- Safraj Shahul Hameed
- Kimberly Marsh
- Freja Kirsebom
- Diogo F.P. Marques
- Angela Rose
- Hanne-Dorthe Emborg
Publication Details
- Journal
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
- Published
- 2025-02-20
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00